Groundbreaking Discovery: Zinc Reactivates p53 Gene for Cancer Treatment
A groundbreaking discovery by Dr. Darren Carpizo could revolutionize cancer treatment. His research, now commercialized through Z53 Therapeutics Inc., focuses on zinc's role in reactivating the p53 gene, a crucial cancer suppressor.
Dr. Carpizo's journey began at Rutgers University, where he started exploring zinc's potential in cancer treatment. In 2012, his team at the University of Rochester discovered that zinc metallochaperones could stabilize and reactivate the p53 gene. This gene, often referred to as the 'guardian of the genome', is the most commonly mutated in cancer and is believed to be a factor in nearly every type of cancer.
Zinc's potential is vast. It can potentially treat over 120,000 cancer patients annually in the U.S. alone. However, common zinc supplements like Zicam cannot deliver zinc to cells. Dr. Carpizo's zinc metallochaperones overcome this barrier, targeting cancer cells specifically. Moreover, raising zinc levels in cells can stabilize a broad range of p53 mutations, expanding the potential patient pool.
Dr. Carpizo's work, now commercialized through Z53 Therapeutics Inc., offers hope for a new era in cancer treatment. With zinc's potential impact on both cancer and infectious diseases like COVID-19, the future looks promising. As the company continues to develop this innovative technology, it brings us one step closer to conquering cancer.
Read also:
- Americans Lose Insurance Under New Tax Legislation, Affecting 10 Million Citizens
- Pro-Life Group Condemns FDA's Approval of Generic Abortion Drug
- Trump Signs Law Defunding Planned Parenthood, Threatening Healthcare Access for Millions
- Historian Ute Frevert Explores Germans' Emotional Bond With Constitutions
